<DOC>
	<DOCNO>NCT01417182</DOCNO>
	<brief_summary>Prostate cancer common cancer among men United States . Through early detection improve local therapy large number men cure . The clinical need include early detection , accurate initial stag detection local recurrence metastasis order permit application appropriate therapy . Therapeutic monitoring prognostic assessment equally important . Imaging play important crucial role meeting clinical need . Positron emission tomography ( PET ) imaging gain important role clinical management cancer patient . 18F-DCFBC novel low molecular weight prostate specific membrane antigen ( PSMA ) -based radiopharmaceutical radiolabeled fluorine-18 positron emitter PET imaging . Preclinical mouse prostate cancer tumor model image study 18F-DCFBC demonstrate high specific uptake PSMA express prostate cancer cell . The investigator assess hypothesis 18F-DCFBC , new positron emission tomography ( PET ) radiopharmaceutical may possess pharmacokinetic pharmacodynamic property represent advance image prostate cancer . This initial phase I study determine biodistribution , pharmacokinetics , prostate specific tumor uptake patient metastatic prostate cancer .</brief_summary>
	<brief_title>Biodistribution Pharmacokinetic Study 18F-DCFBC Prostate Specific Membrane Antigen Based PET Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>Prostate cancer common cancer among men United States . Through early detection improve local therapy large number men cure . The clinical need include early detection , accurate initial stag detection local recurrence metastasis order permit application appropriate therapy . Therapeutic monitoring prognostic assessment equally important . Imaging play important crucial role meeting clinical need . Positron emission tomography ( PET ) imaging gain important role clinical management cancer patient . 18F-DCFBC novel low molecular weight prostate specific membrane antigen ( PSMA ) -based radiopharmaceutical radiolabeled fluorine-18 positron emitter PET imaging . Preclinical mouse prostate cancer tumor model image study 18F-DCFBC demonstrate high specific uptake PSMA express prostate cancer cell . The investigator assess hypothesis 18F-DCFBC , new positron emission tomography ( PET ) radiopharmaceutical may possess pharmacokinetic pharmacodynamic property represent advance image prostate cancer . This initial phase I study determine biodistribution , pharmacokinetics , prostate specific tumor uptake patient metastatic prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients may enrol protocol follow inclusion criterion meet : 1 . Greater equal 18 year age 2 . Histological confirmation prostate cancer 3 . Radiologic evidence new progressive metastatic disease demonstrate anatomical imaging ( CT , MRI , ultrasound ) , bone scintigraphy , 18FSodium Fluoride PET , 18FFDG PET 4 . PSA ≥ 1.0 ng/mL 5 . Can androgen deprivation therapy dose stable ≥ 1 week . 6 . Platelet count &gt; 50,000/mm3 7 . Neutrophil count &gt; 1,000/mm3 8 . Patient judge Investigator initiative mean compliant protocol within geographical proximity make require study visit . 9 . Patients legal representative must ability read , understand provide write informed consent initiation study related procedure . Patients exclude enrollment follow apply : 1 . Karnovsky performance status &lt; 60 2 . Inadequate venous access ( two antecubital equivalent venous access site require study drug injection PK blood sampling , respectively ) 3 . Patient receive permanent prostate brachytherapy implant within last 3 month ( Pd103 implant ) 12 month ( I125 implant ) 4 . Administered radioisotope within 5 physical halflives prior study enrollment 5 . Serum creatinine &gt; 3 time upper limit normal 6 . Total bilirubin &gt; 3 time upper limit normal 7 . Liver Transaminases &gt; 5times upper limit normal 8 . Patient treat investigational drug , investigational biologic , investigational therapeutic device within 30 day prior study radiotracer administration 9 . Prior radiation therapy chemotherapy within 2 week prior study radiotracer administration ( Washout one halflife drug 2 week , whichever long ) . 10 . Prior history malignancy within 3 year , skin basal cell carcinoma .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Patients Advanced Prostate Cancer</keyword>
</DOC>